Galmed Pharmaceuticals (GLMD) AI Stock Analysis

• Market Cap: $3.89M
• Dividend Yield: N/A
• Average Volume (3M): 84.25K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: N/A
• EPS Growth: 70.71%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 5,479,231
• 10 Day Avg. Volume: 86,643
• 30 Day Avg. Volume: 84,246
• PEG Ratio: <0.01
• Price to Book (P/B): 0.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.50
• Enterprise Value/Market Cap: 0.09
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.05
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $0.81 ▲(1.90% Upside)

The score is weighed down mainly by weak financial performance (no revenue, ongoing losses, and continued cash burn), with technicals also bearish as the stock trades below all major moving averages and momentum indicators remain negative. A debt-free balance sheet provides some stabilization but is not enough to offset the core operating risks.

Positive Factors

Strong Equity Position

A strong equity position with no debt provides financial stability and flexibility, allowing the company to focus on R&D without immediate pressure from creditors.

Innovative Product Pipeline

Developing Aramchol for NASH and fibrosis addresses significant unmet medical needs, potentially positioning the company as a leader in liver disease treatment.

Digital Asset Strategy

The digital asset strategy aims to enhance capital efficiency and leverage blockchain growth, potentially providing new revenue streams and financial resilience.

Negative Factors

Zero Revenue and Losses

The absence of revenue and continuous losses highlight operational inefficiencies and reliance on external financing, posing risks to long-term sustainability.

Negative Cash Flow

Negative cash flow indicates operational inefficiencies and dependence on external funding, which can limit the company's ability to invest in growth opportunities.

Reliance on Equity Financing

Heavy reliance on equity financing can dilute existing shareholders and indicates potential difficulty in sustaining operations without new funding.

Galmed Pharmaceuticals Business Overview & Revenue Model

Company Description

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

How the Company Makes Money

Galmed Pharmaceuticals makes money primarily through the development and potential commercialization of its lead product candidate, Aramchol. As a clinical-stage company, Galmed does not currently generate product revenues. Instead, the company relies on funding from public and private investors to finance its research and development activities. In the future, Galmed aims to generate revenue through the successful commercialization of Aramchol, which could include sales, licensing agreements, or partnerships with larger pharmaceutical companies. Collaborations and partnerships could provide upfront payments, milestone payments, and royalties based on sales performance once Aramchol or any other product candidates receive regulatory approval and are brought to market.

Galmed Pharmaceuticals Financial Statement Overview

Summary

Pre-revenue profile with continued net losses and persistent negative operating/free cash flow (TTM FCF about -$6.3M). The key offset is a clean balance sheet with effectively no debt and improving equity/assets, which reduces near-term financial risk but does not resolve ongoing cash burn.

Income Statement

GLMD continues to report no revenue across the historical periods provided, which limits visibility into commercialization progress and keeps profitability entirely dependent on expense control. Losses remain material in both annual periods and TTM (Trailing-Twelve-Months), with net income at -$8.7M in TTM versus -$7.5M in 2024, indicating a modest deterioration. A positive sign is that losses are far smaller than the 2020–2022 range, suggesting the cost base has been reduced meaningfully, but the lack of revenue keeps the earnings profile structurally weak.

Balance Sheet

The balance sheet is relatively conservative from a leverage standpoint, with total debt effectively at $0 in TTM (Trailing-Twelve-Months) and in 2024, which reduces refinancing and interest-rate risk. Stockholders’ equity has improved from $16.3M (2024) to $19.1M (TTM), and total assets increased to $21.6M, supporting near-term financial flexibility. The key weakness is persistent negative returns on equity (about -0.48 in TTM), reflecting ongoing losses that can pressure equity over time if cash burn continues.

Cash Flow

Cash generation remains a core challenge: operating cash flow and free cash flow are negative in every period shown, including -$6.3M in TTM (Trailing-Twelve-Months) and -$5.9M in 2024. While cash burn has improved dramatically versus 2020–2022 levels (when annual operating cash outflows were much larger), the company is still consuming cash with no operating inflows from revenue. Free cash flow improvement is a positive trend, but the business remains dependent on external funding or existing cash resources to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-83.00K	-31.00K	-35.00K	-42.00K	-39.00K
EBITDA	-7.09M	-7.42M	-6.87M	-17.62M	-32.84M	-30.17M
Net Income	-8.70M	-7.52M	-6.91M	-18.57M	-31.95M	-27.61M
Balance Sheet
Total Assets	21.58M	18.50M	16.63M	16.56M	36.60M	52.38M
Cash, Cash Equivalents and Short-Term Investments	19.05M	15.33M	12.64M	13.79M	34.81M	50.89M
Total Debt	0.00	0.00	41.00K	44.00K	229.00K	216.00K
Total Liabilities	2.47M	2.17M	2.75M	3.14M	6.11M	8.23M
Stockholders Equity	19.11M	16.33M	13.88M	13.42M	30.50M	44.15M
Cash Flow
Free Cash Flow	-6.34M	-5.88M	-6.14M	-18.50M	-32.90M	-26.33M
Operating Cash Flow	-6.34M	-5.88M	-6.14M	-18.50M	-32.89M	-26.29M
Investing Cash Flow	-8.35M	-1.11M	800.00K	17.56M	11.46M	16.54M
Financing Cash Flow	8.29M	8.79M	6.18M	70.00K	17.37M	768.00K

Galmed Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.79
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GLMD, the sentiment is Negative. The current price of 0.79 is below the 20-day moving average (MA) of 0.80, below the 50-day MA of 0.88, and below the 200-day MA of 1.35, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 31.77 is Neutral, neither overbought nor oversold. The STOCH value of 1.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GLMD.

Galmed Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JAGX	45 Neutral	$2.52M	-0.02	-370.95%	―	12.45%	-544.23%
CLDI	45 Neutral	$7.31M	-0.11	―	―	―	87.42%
GLMD	44 Neutral	$3.89M	-0.19	-46.34%	―	―	70.71%
QNRX	44 Neutral	$4.24M	-0.02	-655.85%	―	―	-228.89%
AIM	40 Underperform	$3.77M	-0.06	―	―	-41.05%	57.35%

Galmed Pharmaceuticals Corporate Events

Galmed Pharmaceuticals Receives Nasdaq Minimum Bid Price Deficiency Notice

On January 30, 2026, Galmed Pharmaceuticals announced that it had received a notification letter from Nasdaq stating that the company is not in compliance with the exchange’s minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market. Nasdaq has granted Galmed a 180‑day grace period, from January 29, 2026 to July 28, 2026, to regain compliance, which would be achieved if its ordinary shares close at or above $1.00 for at least ten consecutive business days. The notice has no immediate effect on the listing or trading of Galmed’s shares, which will continue to trade under the symbol GLMD during the compliance period, but failure to restore the bid price in time could ultimately result in delisting, underscoring ongoing pressure on the company’s market valuation and listing status.

The most recent analyst rating on (GLMD) stock is a Hold with a $0.79 price target. To see the full list of analyst forecasts on Galmed Pharmaceuticals stock, see the GLMD Stock Forecast page.

Galmed Pharmaceuticals’ Aramchol Abstract Accepted for HEP-DART 2025 Presentation

On December 8, 2025, Galmed Pharmaceuticals announced the acceptance of a late-breaking abstract for its lead drug candidate, Aramchol, to be presented at the HEP-DART 2025 meeting. The abstract highlights the potential of Aramchol in combination with regorafenib to enhance treatment efficacy in hepatocellular carcinoma and other gastrointestinal cancers. This development has led to the initiation of a Phase 1/2 clinical trial by VCU Massey Comprehensive Cancer Center, with enrollment planned for 2026. The successful presentation and subsequent clinical trial could significantly expand Galmed’s oncology pipeline and create value for stakeholders.

Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy

On December 4, 2025, Galmed Pharmaceuticals announced the grant of a new use patent in South Korea for a combination therapy involving its lead compound, Aramchol, and Madrigal Pharmaceuticals’ Rezdiffra (Resmetirom) for treating non-alcoholic steatohepatitis (MASH) and liver fibrosis. This patent, which extends Aramchol’s protection worldwide until July 2042, marks a significant step in the company’s strategy to lead in the NASH/MASH combination therapy market. The announcement underscores the industry’s shift towards combination therapies to address complex diseases like MASH, highlighting Aramchol’s excellent safety and tolerability as a key advantage.

Galmed Pharmaceuticals Expands Aramchol’s Clinical Applications and Strengthens Financial Position

On December 1, 2025, Galmed Pharmaceuticals issued a CEO letter to shareholders highlighting the company’s recent achievements and future plans. The company has expanded its therapeutic focus beyond liver disease, generating new data supporting Aramchol’s broader clinical development path in oncology and cardiometabolic indications. Galmed maintains a strong cash position with $19.2 million and minimal debt, allowing it to continue its development plans without aggressive capital raises. The company is advancing Aramchol in combination therapies for MASH and gastrointestinal oncology, with plans for further clinical trials. These developments position Galmed for significant growth opportunities and potential FDA approval, enhancing its market presence and stakeholder value.

Galmed Pharmaceuticals Reports Q3 2025 Financials and Research Breakthroughs

Galmed Pharmaceuticals announced its financial results for the third quarter of 2025, highlighting a net loss of approximately $2.0 million, an increase in research and development expenses, and a decrease in general and administrative expenses compared to the same period in 2024. The company also reported significant progress in its research collaborations, including promising results from a study on Aramchol’s effectiveness in combating drug resistance in gastrointestinal cancers, and a successful Phase 1 study of Aramchol Meglumine, which could enhance its market positioning and stakeholder confidence.

Galmed Pharmaceuticals Reports Promising Results from Aramchol Meglumine Study

On November 18, 2025, Galmed Pharmaceuticals announced significant top-line results from its AM-001 Phase 1 Bioavailability Study of Aramchol meglumine. The study revealed that Aramchol meglumine granules have a considerably higher bioavailability compared to Aramchol free acid tablets, with potential implications for improved patient adherence and reduced drug costs. These findings support the advancement of Aramchol meglumine into Phase 2 oncology studies planned for the first half of 2026, marking a pivotal step in the drug’s development and commercialization strategy.

Galmed Pharmaceuticals Reveals Promising Results in Oncology Drug Combination Study

Galmed Pharmaceuticals announced on November 17, 2025, the top-line results of their oncology mechanism of action studies involving a three-drug combination of Aramchol, Stivarga®, and Metformin, which demonstrated significant enhancement in killing gastrointestinal tumor cells both in vivo and in vitro. This combination has the potential to serve as a new fixed-dose treatment and a life-cycle IP strategy for Bayer’s Stivarga® as its patents near expiration, with plans to enter Phase 1b clinical trials in early 2026, potentially expanding Galmed’s pipeline and creating value for stakeholders.